Celltrion, Inc. (KRX:068270)
159,300
+600 (0.38%)
Last updated: May 30, 2025
Celltrion Revenue
Celltrion had revenue of 841.91B KRW in the quarter ending March 31, 2025, with 14.24% growth. This brings the company's revenue in the last twelve months to 3.66T, up 58.14% year-over-year. In the year 2024, Celltrion had annual revenue of 3.56T with 63.45% growth.
Revenue (ttm)
3,662.23B
Revenue Growth
+58.14%
P/S Ratio
9.24
Revenue / Employee
1.53B
Employees
2,391
Market Cap
33.84T
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3,557.30B | 1,380.87B | 63.45% |
Dec 31, 2023 | 2,176.43B | -107.54B | -4.71% |
Dec 31, 2022 | 2,283.97B | 390.57B | 20.63% |
Dec 31, 2021 | 1,893.40B | 44.29B | 2.39% |
Dec 31, 2020 | 1,849.12B | 720.66B | 63.86% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,898.69B |
ALTEOGEN | 151.65B |
Yuhan | 2,114.76B |
HLB Co., Ltd. | 74.64B |
SK Biopharmaceuticals | 578.00B |
Peptron | 4.30B |
PharmaResearch | 392.31B |
LigaChem Biosciences | 146.42B |
Celltrion News
- 18 days ago - Celltrion to Cancel $72 Million in Shares to Boost Shareholder Value - GuruFocus
- 4 weeks ago - Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing ... - GuruFocus
- 6 weeks ago - Shilpa Medicare settles Celltrion arbitration case with $3.4 million agreement - Business Upturn
- 2 months ago - Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025 - Financial Post
- 2 months ago - Celltrion’s Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada - Financial Post
- 5 months ago - FDA approves Celltrion's biosimilar of J&J's Stelara - Seeking Alpha
- 6 months ago - Health Canada approves Celltrion’s Omlyclo™ (CT-P39), the first and only omalizumab biosimilar in Canada - Financial Post